Novartis' experimental drug fails pivotal trial for rare neuromuscular disease

Novartis reported that its experimental therapy for a rare neuromuscular disorder did not improve muscle function in a pivotal study, missing its primary endpoints.

The failure represents the company's second major trial collapse within a few days, prompting heightened scrutiny of its development program in this area.

Separately, the European Commission approved a €464 million German payment to Sanofi to ensure continued insulin supplies, underscoring ongoing regulatory and supply challenges in the pharmaceutical sector.